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NOTCH DRIVES PROLIFERATION AND RADIATION RESISTANCE OF CANCER 
STEM CELLS IN ADENOID CYSTIC CARCINOMA. Michael T. Chang, Alex 
Panaccione, Beatrice E. Carbone, Christopher A. Moskaluk, Sergey V. Ivanov, Wendell 
G. Yarbrough. Section of Otolaryngology, Department of Surgery, Yale University, 
School of Medicine, New Haven, CT. 
 
Adenoid cystic carcinoma (ACC) of the salivary gland is an indolent but highly lethal 
neuroinvasive tumor with a propensity for radiation resistance, recurrence, and 
metastasis. Molecular understanding of this rare tumor has been hampered by the absence 
of validated in vitro models and a limited number of xenografts. Therapeutic options for 
ACC are limited to surgery and radiation and are associated with an unacceptably low 
rate of cure. Cancer stem cells (CSC) are an attractive therapeutic target, and 
understanding their role in ACC may advance therapy. Our objectives were: 1) to 
establish and validate ACC cell cultures, 2) to determine if CSC exist in ACC, and if so, 
isolate and characterize these cells in ACC, and 3) to identify new therapeutic targets for 
ACC. To culture ACC and to isolate and initially characterize CSC from ACC, we 
modified a ROCK inhibitor-based cell culture technique, identified CD133 (PROM1) as a 
cell surface marker of CSCs, and used immunomagnetic cell sorting to separate and 
characterize RNA and protein expression in these cells. We found that CD133+ cells 
expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice 
more readily than CD133- cells. Depletion of NOTCH1 and SOX10 in cultured ACC 
induced death of CD133+ cells, indicating their essential roles in maintenance of 
stemness. An inhibitor of Notch activation, DAPT, selectively depleted CD133+ cells in 
vitro, sensitized CD133+ cells to radiation, and inhibited growth of ACC tumor in vivo.  
These results establish the presence of a previously uncharacterized population of 
CD133+ cells with neural stem properties in ACC whose survival is dependent on 
NOTCH1 and SOX10.  Sensitivity of ACC cells to Notch inhibition offer new 
opportunities for targeted therapy in this orphan tumor. 
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Adenoid Cystic Carcinoma Overview 
Background 
 Adenoid cystic carcinoma (ACC) comprises approximately one quarter of all 
salivary gland malignancies and is one of the most relentless, unpredictable, and fatal 
cancers of the head and neck region. First documented by French physicians Robin and 
Lalboulbene in their 1853 publication Memoire sur trois productions morbides 
nondescrites [Memoirs of three undescribed morbid productions], the mysterious and 
lethal nature of this disease was evident even in its earliest descriptions (1). In 1859, 
Prussian surgeon Theodor Billroth termed this disease “cylindroma,” naming it for its 
characteristic histological appearance of cylindrical clusters of cells (2). Also noting its 
distinct histology, Spies is credited with coining the term “adenoid cystic carcinoma” in 
1930 (3), a term popularized in the medical community in 1953 when Foote and Frazell 
classified several salivary gland tumor types in their seminal Cancer article (4). They 
were also the first to note that ACC spanned a wider spectrum of histological types in 
addition to its classic tubular appearance. 
 Since the earliest reports of ACC, physicians have noted several hallmark 
characteristics, including its tendency to involve nerves (4), recur (2), metastasize, and 
ultimately kill patients (5). In 1974, Conley and Dingman noted ACC to be “one of the 
most biologically destructive and unpredictable tumors of the head and neck” (5). Despite 
numerous clinical trials involving multiple treatment modalities and pharmaceutical 




 While salivary gland malignancies are relatively rare, ACC represents a 
significant portion (22%) of these cancers (6). Worldwide yearly incidence is estimated 
to be 1 to 1.3 cases per 100,000 people, translating to roughly 1,200 new cases per year in 
the US, making ACC the second most common salivary gland malignancy overall behind 
mucoepidermoid carcinoma (7).  
In the parotid gland, ACC is the second most commonly occurring cancer type, 
occurring in 7-18% of cases, however ACC is the most common cancer type in the 
sublingual gland (20%), submandibular gland (20%), and minor salivary glands (35-58%) 
lining the upper aerodigestive tract (7-10). While most often found in the minor salivary 
glands of the tongue, buccal mucosa, and palate (7, 9), ACC has also been reported to 
occur in other sites of the airways, including the paranasal sinuses, lips, larynx, trachea, 
and nasolacrimal tract (11). Outside of the aerodigestive tract, ACC has been reported to 
arise in other glandular structures, including the breast (12), prostate (13), skin (14), and 
female genital tract (15).     
 Salivary ACC typically affects people in their 5th or 6th decade of life, with a 
mean age of 57 years (16). ACC has a slight tendency to occur in females (59%), and 
approximately 80% of reported cases occur in Caucasians (16). Familial history, toxic 
exposures, or environmental exposures have not been associated with increased risk of 
ACC (16, 17). 





 The classical behavior of ACC is somewhat paradoxical: growth is slow and 
indolent, but the cancer is relentless and progressive (11). Initially, ACC most commonly 
presents as a firm mass in the head or neck region that slowly enlarges over months to 
years. Depending on its location, the mass may occasionally present with pain, numbness 
or ulceration (18). Given its tendency to invade nerves, ACC of the parotid gland can 
present with facial nerve paralysis in up to one third of patients (9).  
The tumor’s slow growth often leaves it amenable to surgical removal, however 
local recurrences occur frequently, estimated in 16-39% cases (11, 18). Unlike other head 
and neck cancers, regional lymph node metastases of ACC to the neck rarely occur, seen 
in less than 10% of cases (19). However, distant metastases occur in 35-50% of cases, 
most commonly to the lung (20). ACC also spreads to the bones, liver, and central 
nervous system (20, 21). Complications resulting from distant metastases are often the 
cause of death, with a mean time between lung metastases detection and death of 32.3 
months, and a mean time between other metastatic site detection and death of 20.6 
months (22).  
 
Diagnosis 
 Fine needle aspiration (FNA) is the most widely used diagnostic tool in the initial 
evaluation of a head and neck mass suspicious for neoplasm. Cytologic diagnosis is 
possible in most cases, with FNA accurately identifying about 77% of ACC cases (23). 
Cytologic analysis for ACC typically shows basaloid tumor cells clustered around 
globules containing eosinophilic extracellular matrix material (23).  Clinicians must be 
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careful to distinguish ACC from pleomorphic adenoma, the most common benign tumor 
of the salivary gland, as the two can have a very similar cytologic appearance. Largely 
because of the cytologic similarity between ACC and benign tumors, the false negative 
rate for FNA is 17%, therefore clinicians must interpret FNA results in the context of 
other clinical findings (23). 
 Radiographic imaging by computed tomography (CT) or magnetic resonance 
imaging (MRI) is used for evaluating the extent of tumor spread. MRI with gadolinium 
contrast is important in assessing for nerve involvement. ACC tumors tend to have poorly 
defined borders and homogeneous enhancement on T1-weighted MRI imaging, however 
there are no objective radiographic signs specific to ACC versus other salivary tumor 




 ACC is composed of two cell types within the salivary gland: myoepithelial cells 
and ductal cells (9). Classically, there are three histological subtypes of ACC: cribiform, 
tubular, and solid. Cribiform is the most common histology and is predominantly 
composed of “punched out” pseudocysts amongst small ductal cell islands. Tubular 
histology shows a palisading pattern of well-formed ducts lined by myoepithelial cells. 
Solid histology involves solid sheets of both cell types with thin strands of intervening 
stroma. Solid histology has historically been associated with a worse prognosis (25); 
however, later studies have shown that tumor stage rather than histologic grade is a more 
accurate prognostic indicator (26). While classically these histological subtypes have 
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been viewed as distinct, the majority of tumors contain a mixture of these patterns (9). In 
all subtypes, perineural invasion is very common (60% of cases), even in early stage 
tumors (27). 
 Immunohistochemical (IHC) stains aid in the diagnosis of ACC. Characteristic 
expression for ACC includes carcinoembryonic antigen (CEA), muscle specific actin 
(MSA), Ki-67, and several cytokeratins (28). ACC stains very similarly to another low-
grade cancer, polymorphous low grade adenocarcinoma (PLGA); however, cellular 
atypia and high Ki-67 index can assist in identifying ACC (9). Despite the histological 
appearance of a low-grade cancer, all cases of ACC are considered high-grade salivary 
gland neoplasms given the aggressive clinical behavior.   
 
Management 
 For ACC of a major salivary gland, surgical excision of the entire involved gland 
is the primary treatment option. Treatment of minor salivary gland tumors depends on 
location, with oral cavity lesions typically being excised and lesions closer to the skull 
base undergoing endoscopic removal or gamma knife therapy. Negative margins are 
important to obtain, as margin status has been shown to be a significant predictor of local 
recurrence (29). Interestingly, however, margin status has no significant bearing on rate 
of distant metastasis (29). Because regional lymph node metastases are relatively rare in 
ACC, neck dissections are typically reserved for cases where there is clinical evidence of 
neck node metastasis (19).  
 Postoperative radiotherapy is often employed, as studies have shown it to 
significantly improve local control for both early and late stage tumors (27); however, 
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opposing studies have found that postoperative radiation does not significantly affect 
local control except in advanced stages or cases with positive margins (30, 31). 
Importantly, the addition of radiation has no significant effect on rates of distant 
metastasis or overall survival (27, 30). Despite treatment with postoperative radiotherapy, 
radiation resistance remains an issue as local recurrence occurs in approximately one-
third of cases (11, 18).    
To date, no systemic agents have been shown to induce a significant response in 
the treatment of ACC, thus chemotherapy is typically reserved for palliative measures in 
unresectable or metastatic disease (32). 
 
Prognosis 
 The 5-year overall survival is 85-90%, however the 15-year overall survival rate 
is 35-40% (25, 27, 30), reflective of a protracted clinical course typical of ACC. Factors 
associated with worse prognosis include positive resection margins, major nerve 
involvement, and advanced stage (27, 33). While it is possible for patients to live many 
years with this indolent cancer, long-term disease-free survival is dismal being only 42% 
at 5 years and 29% at 10 years (34). The majority of ACC cases end with death resulting 
from complications of metastatic disease (22). 
 
Molecular Landscape of ACC 
Mutational Profile 
 Because the molecular drivers of ACC remain largely unknown, next-generation 
sequencing methods have been employed to elucidate its mutational landscape. Three 
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recent studies performed genome and whole exome sequencing, looking at a combined 
108 ACC specimens with matched normal DNA (35-37). All studies found a very low 
somatic mutation rate, with one analysis reporting 13 mutations per exome (35), and 
another study reporting a mean of 22 somatic mutations per sample, correlating to a non-
silent mutation rate of 0.31 mutations per megabase (36). ACC was also found to have a 
highly diverse mutational profile, with mutations seen in chromatin state regulators, DNA 
damage pathways, and growth factor signaling.  
All studies identified t(6;9) fusions of the MYB-NFIB genes, as well as somatic 
mutations in the MYB gene, aberrations seen in the majority of ACC cases (38). The 
t(6;9) MYB-NFIB fusion has historically been the most commonly cited marker of ACC, 
as it is unique to this tumor compared with other head and neck cancers (38). Recently, a 
t(8;9) fusion of another MYB family member, MYBL1, and NFIB has been identified in 
approximately 30% of t(6;9)-negative cases (39). MYB is a transcription factor with a 
plethora of targets and acts to both activate and inhibit transcription of its targets. 
Activation of MYB has several downstream effects including cellular proliferation and 
inhibition of terminal differentiation, thus it is hypothesized that the translocation induces 
pathologic changes of these cellular processes (40). MYB alterations have a significant 
association with recurrence and metastasis (39), and the common presence of mutations 
and fusions of MYB family members suggest that activation of this pathway is critical, if 
not required, in development or maintenance of ACC. 
Whole exome sequencing also found mutations in the FGF/IGF/PI3K pathway in 
30% of cases (36). Moreso, samples with phosphatidylinositol 3-kinase (PI3K) mutations 
were all from solid histology tumors, traditionally seen as the most aggressive variant of 
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ACC. Fibroblast growth factors (FGF) and insulin-like growth factors (IGF) are known to 
be potent oncogenic activators of PI3K (41). Further research into this pathway may 
present a potentially promising therapeutic target for a subset of ACC cases.  
 
Expression Changes 
To identify differentially expressed genes involved in ACC formation or 
maintenance, microarray gene expression analyses surveyed 8920 genes in 15 ACC 
specimens and 5 normal salivary glands (42). Given the myoepithelial origin of the 
tumor, it was not surprising that several genes involved in myoepithelial differentiation 
are upregulated in ACC. Notable genes that are highly overexpressed included SOX4, a 
transcription factor involved in neural and immunologic cell development, AP-2γ, an 
upstream effector of oncogene c-Kit, and casein-kinase 1ε and frizzled-7, both members 
of the Wnt/β-catenin pathway (42).  
IHC examination of 27 ACC specimens found c-Kit (CD117) overexpression in 
90% of ACC cases (43). c-Kit is a tyrosine kinase receptor involved in numerous 
physiologic processes including hematopoiesis, spermatogenesis, and cell migration (44) 
and is a transcriptional target of MYB (45). c-Kit is a known oncogenic driver in other 
types of cancers such as seminomas and gastrointestinal stromal tumors (GISTs) (46, 47), 
and c-Kit inhibition results in dramatic regression of GISTs (48). In ACC, c-Kit levels are 
associated with poorer prognosis (43). Interestingly, c-Kit has been used to isolate 
salivary progenitor cells, suggesting it may play a role in stem cell maintenance in ACC. 
Though initially promising, however, tyrosine kinase inhibitors of c-Kit have failed to 
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induce a therapeutic response in several clinical trials treating patients with ACC (49, 
50). 
SOX10, a transcription factor required for maintenance and migration of neural 
crest stem cells, is also highly expressed in both primary ACC specimens and ACC 
xenografts compared with normal salivary tissue and other salivary tumor types (51). 
Microarray analyses indicating high SOX10 expression in ACC was confirmed by IHC. 
In silico analysis identified genes co-expressed with SOX10 and defined the SOX10 gene 
signature as unique to ACC compared with other salivary gland malignancies (51). 
Interestingly, SOX10 is also expressed in basal-type breast carcinoma specimens as 
confirmed by IHC, and components of the larger SOX10 gene signature are preserved in 
basal-like breast cancers. The required role for SOX10 in neural crest stem cells, the 
derivation of myoepithelial cells from neural crest, and the involvement of myoepithelial 
cells in ACC and basal-like breast cancer suggest that SOX10 may play a critical role in 
supporting the stem cell features in ACC and a subset of breast cancer, as well as other 
cancers containing neural crest derivatives (51). 
 Fatty-acid binding protein 7 (FABP7), normally a chaperone for lipids between 
cytoplasm and nucleus, is part of the SOX10 signature and is highly overexpressed in 
microarray studies of ACC xenografts versus normal salivary glands (52). In ACC, 
FABP7 is highly expressed in myoepithelial cell nuclei, suggesting a potential role in 
development or proliferation of ACC, as nuclear FABP7 is present in rapidly 
proliferating cells of other cancers (53, 54). Although the precise role of FABP7 in ACC 
development or maintenance is not known, its expression correlates with aggressive 
behavior and poor prognosis in ACC (52). In other cancers of neural crest derivatives 
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such as glioma, FABP7 has been implicated as a critical player in stem cell maintenance 
(55), and the presence of nuclear FABP7 is associated with poorer prognosis compared to 
cytoplasmic FABP7 (53). The biological consequences have not been well characterized, 
however FABP7 has been identified as a target of Notch signaling (56). As understanding 
of the Notch pathway in ACC becomes better understood, so may the role of FABP7. 
 
Epigenetic Alterations 
 Given the overall low mutational load in ACC and the relatively high number of 
mutations involving chromatin regulators (37), it is likely that epigenetic changes play 
critical roles in driving ACC. Analysis of CpG island DNA methylation levels in 16 ACC 
specimens with matched normal tissue (57) revealed hypermethylated genes including 
initiators of apoptosis or differentiation such as BCL2L11, transcription factors such as 
EN1, GBX2, FOXL1, and NR2F2, and effectors of metabolism including XRN2, INSRR, 
and PNLIPRP1, suggesting that epigenetic silencing of these genes may play an 
important role in ACC. Significant hypomethylated genes in ACC include DOCK1, 
involved in cell surface extension, and PARVG, involved in cell adhesion (57). The 
biological consequences of these epigenetic changes require further study to determine 
their functional significance and possible therapeutic implications. 
 
Notch Signaling in ACC 
 Notch signaling is a highly conserved pathway that mediates cellular 
differentiation and growth. Canonical Notch signaling is initiated by five ligands, Delta-
like 1 (DLL1), DLL3, DLL4, Jagged-1 (JAG1), and JAG2 that bind to Notch receptors 
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and trigger proteolytic cleavage by gamma-secretase. Notch cleavage releases the Notch 
intracellular domain (NICD) that translocates to the nucleus where it imposes its 
regulatory activity as a transcription factor (58). NOTCH can serve as an oncogene like it 
does in breast cancer and T-cell acute lymphoblastic leukemia (58, 59), or as a tumor 
suppressor, like in squamous cell carcinoma of the head and neck (HNSCC) (60). The 
specific role of Notch signaling in ACC has yet to be fully elucidated.   
Gene expression comparison between ACC and normal salivary tissue identified 
that several genes in the Notch signaling pathway such as NOTCH3 and JAG1 were 
highly expressed in cancers (42). In addition, NOTCH1 mutations were found in ACC 
xenografts (58), and these exonic mutations are known to induce ligand-independent 
release of NICD or stabilize the active NICD through deletion of the C-terminal PEST 
domain. Interestingly, NOTCH1 activation, as measured by NICD, predicts response to 
gamma-secretase inhibitors in breast cancer and ACC models (58). Further supporting a 
role for Notch activation in ACC, whole exome sequencing identified missense or 
truncating mutations in NOTCH1 and NOTCH2 in a low number of primary tumors, 
though functional consequences of these NOTCH mutations were not determined in these 
particular cases (35). As the role of Notch signaling in ACC becomes clearer, more 
therapeutic opportunities for ACC may open, especially as Notch inhibition becomes an 






In Vitro and In Vivo Tools for ACC Research 
Cell Lines 
 Particularly in rare cancers where original tumor tissue is scarce, reliable in vitro 
models can play a critical role in the study of its molecular and biological properties, as 
well as testing of potential therapeutic agents. At one point, several cell lines exchanged 
by many academic institutions were used to study ACC, including ACC2, ACC3, 
ACCM, ACCS, ACCNS, and CAC2. However, in 2009, short tandem repeat (STR) DNA 
fingerprint analysis examining eight loci of nucleotides was performed with cross-
referencing of these lines with national databases (61). Unfortunately, all six cell lines 
were either improperly identified as ACC or contaminated. ACC2, ACC3, and ACCM 
were found to be HeLa cells, ACCS were T24 urinary bladder cancer cells, ACCNS were 
mouse cells, and CAC2 were rat cells (61). Misidentification of these cell lines nullified 
the validity of all work derived from these cell lines, and since then, researchers have had 
a great need for new in vitro tools to study ACC.   
 After the devastating results disqualifying previous ACC cell lines, another cell 
line, SACC-83, derived from a minor salivary gland cancer has been described. Passage 
of this cell line through a mouse was used to derive a line with higher metastatic 
potential, SACC-LM (62, 63). STR analysis has shown that these cells are distinct from 
HeLa cells, however a comparison with public databases has yet to be reported to ensure 
a unique signature. Additionally, distribution of these cell lines has been very limited 
outside of China.  
 In 2014, an additional cell line, MDA-ACC-01, was developed from a base of 
tongue ACC (64). STR analysis indicated a unique phenotype and early cultures 
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proliferated well. However MDA-ACC-01 began to senesce after passage 7, requiring 
immortalization with human telomerase transcriptase. Additionally, the properties of 
cultured cells may differ from those of the original tumor, with loss of the known MYB-
NFIB translocation reported in later passages of this cell line (64).  
 
Patient-Derived Xenografts 
Several patient-derived xenograft (PDX) models of ACC were developed and 
have been distributed to several research groups focused on ACC (65). Patient tumor 
tissue was successfully propagated in the subcutaneous flanks of immune deficient nude 
mice in 17 of 23 attempts (74%). Tumors were confirmed to be ACC by histologic 
analysis, IHC characterization, gene expression profiling, and the detection of the MYB-
NFIB fusion. Karyotype profiling confirmed that xenografted tumors were derived from 
the parent tumor (65).  
In addition to serving as reliable preclinical models of disease, xenografts also 
serve as a way to expand available tumor tissue, which is particularly useful in rare 
cancers like ACC. However, PDX models have their limitations in research, namely 
increased maintenance cost, facility space, and distribution difficulty.  Furthermore, PDX 
models do not offer the same ability to manipulate gene expression or to perform high 







Systemic Single-Agent Cytotoxics 
 Because recurrence and metastasis occur frequently despite surgery and radiation, 
multiple clinical trials have been undertaken to assess the utility of systemic therapy in 
ACC. Despite over 30 phase II clinical trials enrolling patients with ACC since 1985, no 
successful single-agent or combinatorial regimens are approved for ACC treatment (32).  
 Single-agent treatments with traditional cytotoxic drugs have largely failed to 
achieve objective responses. In eight trials of single-agent cytotoxic regimens of 
gemcitabine (66), paclitaxel (67), cisplatin (68, 69), mitotraxone (70, 71), epirubicin (72), 
and vinorelbine (73), major objective responses occurred in 18 of 141 (12.8%) of patients 
with recurrent and/or metastatic disease (32). For those cases that did respond to 
treatment, durations of response were short, ranging from 5 to 20 months.  Of all single-
agent therapies, platinum-based regimens with cisplatin were most effective, achieving an 
objective response in 2 of 13 patients, though the reported durations of response were a 
short 5 and 8 months (69). Disease stabilization was a more common finding in these 
trials, reported in 64 of 111 (57.7%) patients (32). However, durations of effect were 
again short, with a maximum reported stabilization period of 30 months. Furthermore, in 
ACC it can be difficult to distinguish treatment-induced disease stabilization given the 
indolent natural course of the disease. In recognition of this point, some trials have begun 





Combinatorial Cytotoxic Regimens 
 Combinatorial regimens of traditional cytotoxic agents have also failed to produce 
broad sustained effects. A review of 17 trials of combinatorial chemotherapy found that 
35 of 143 (24.5%) cases demonstrated an objective response (32). Cisplatin and 
doxorubicin were most commonly tested, and they were employed in combination with 
cyclophosphamide in four trials (74-77). These trials reported the highest objective 
response rates occurring in 9 of 36 (25%) patients; however duration of response was 
short, ranging from 5 to 16 months (75, 77). Though results were slightly better than 
single agent trials, combinatorial cytotoxic therapy also failed to achieve sustained 
responses. Higher rates of toxicity were also seen in combinatorial compared to single-
agent therapy (73). 
In addition to lack of prolonged response time, another major issue with standard 
cytotoxic treatment is the lack of broad effectiveness. Because of the rarity of ACC, large 
patient trials are very difficult to organize, and it is thus difficult to perform subset 
analyses to reliably identify patient or clinical characteristics predicting response. Despite 
failure to induce objective responses, chemotherapeutic agents still play a significant 
palliative role in ACC management, with symptomatic relief reported in 30-70% of 
single-agent treatments and 25-64% of combinatorial regimens (32).   
 
Molecularly Targeted Therapies 
Given the discovery of high c-Kit expression in 90% of ACC tumors, imatinib, a 
tyrosine kinase inhibitor (TKI), has undergone multiple trials with the aim of blocking c-
Kit signaling. Six trials of have assessed imatinib activity in a cumulative 71 ACC 
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patients, five of which found zero objective responses (49, 50, 78-80) and one of which 
saw two objective responses (79). One trial also assessed the effect of adding cisplatin to 
imatinib, reporting three patients with partial responses in the combination group versus 
none in the imatinib only group (81).   
As in other cancers, epidermal growth factor receptor (EGFR) is overexpressed in 
ACC and has been correlated with tumor grade (82), prompting the trial of EGFR 
inhibitors. Gefitinib, the first inhibitor of EGFR’s tyrosine kinase domain, was studied in 
18 patients with recurrent and/or metastatic ACC, but no objective responses were seen 
(83). Lapatinib, a TKI targeting EGFR and erbB2, was tested in 19 patients with ACC 
positive for EGFR and/or erbB2. No objective responses were reported, but nine patients 
(47%) had disease stabilization lasting more than 6 months (84). Cetuximab, a 
monoclonal antibody inhibitor of EGFR, was trialed in 23 patients with recurrent and/or 
metastatic ACC (85). No responses to therapy were observed, but eight patients (35%) 
had a disease stabilization lasting a median time of 4.5 months (85). Another study trialed 
cetuximab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy in 12 patients with 
metastatic EGFR-positive ACC and cetuximab plus cisplatin with concomitant 
radiotherapy in nine patients with locally advanced EGFR-positive ACC (86). Compared 
to historical outcomes, results were favorable, with objective responses occurring in four 
(44%) patients with locally advanced disease and five (42%) patients with metastatic 
disease (86). These results suggest that regimens combining biologic inhibitors, platinum-
based chemotherapy, and radiotherapy may be a viable treatment approach in ACC.  
Studies of ACC have shown mutations and an overexpression of members in the 
fibroblast growth factor receptor (FGFR) signaling pathway (35, 36), warranting testing 
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of fibroblast growth factor receptor inhibition. A recent phase II study has assessed the 
efficacy of oral dovitinib, a multi-kinase inhibitor of FGFR, vascular endothelial growth 
factor receptors (VEGF), and platelet-derived growth factor receptors (PDGFR), in 32 
patients with unresectable or metastatic ACC (87). There were no complete responses, 
one partial response (3%), and 30 cases (94%) with disease stabilization, though the 
authors note that it was difficult to determine if these cases were truly results from 
treatment rather than natural disease course (87). 
Sunitinib has been another drug of interest, given its ability to inhibit multiple 
targets identified as critical in ACC, including c-Kit, VEGF, PDGF, and the RET 
oncogene. A phase II study studied the efficacy of sunitinib in 13 patients with 
progressive, recurrent, or metastatic ACC (88). Again, however, no responses were seen, 
while 11 patients (85%) demonstrated disease stabilization (88).  
Bortezimib, an inhibitor of the 26S proteasome and thought to function at least 
partially through inactivation of NF-kB, has been studied as a single-agent and in 
combination with doxorubicin in a phase II trial of 24 patients with progressive or 
metastatic ACC (89). Though well tolerated, no objective responses were seen in either 
treatment group, and only one partial response was seen in the combination group (89).  
mTOR, a master cell growth regulator and target of PI3K, has been implicated as 
an ACC driver and inhibition in preclinical trials have induced cell death in ACC (90), 
prompting a phase II study of everolimus, an mTOR signaling inhibitor. Out of 34 
patients with progressive unresectable ACC, 27 patients (79%) showed disease 
stabilization, however no responses were observed (91). As toxicities were very well 
tolerated, mTOR inhibition may play a role in controlling unresectable disease; however, 
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Several preclinical trials have shown promise with regard to potential molecular 
targets and are prompting more phase II clinical trials that are currently ongoing. Agents 
under investigation include selinexor (inhibitor of CRM, EGFR, HER2, FGFR, c-Kit), 
eribulin (inhibitor of mitosis), pembrolizumab (PD-1 inhibitor), and vorinostat (histone 
deacetylase inhibitor). 
Despite numerous trials with small molecule inhibitors, inducing a reliable 
response in ACC remains elusive. While several of the agents studied achieved stable 
disease states lasting more than 6 months, more long-term follow up is required to 
determine control of late disease progression, given the naturally protracted course of 
ACC.  
The poor track record of clinical trials using cytotoxic or targeted agents in ACC 
likely represents inherent resistance of these cells and point to the inadequacy of pre-
clinical studies to predict response. Clearly, understanding of the true molecular drivers 
of ACC remain poor, suggesting that new tools for study and biologic innovation is 
needed to make therapeutic advances in ACC. A potentially exciting area of investigation 
is the role of Notch in ACC. Building off recent data implicating Notch importance in 
ACC (35, 42, 58), three phase I clinical trials studying the efficacy of Notch inhibitors in 
ACC are underway (92). One trial is investigating the efficacy of brontictuzumab (OMP-
52M51), a monoclonal antibody against the Notch1 receptor in refractory and recurrent 
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cases. Two independent trials are assessing the efficacy of BMS-906024, a new pan-
Notch inhibitor, with one study utilizing it as a single-agent and the other in combination 
with traditional chemotherapy (92). 
 
Cancer Stem Cells 
Cancer Stem Cell Theory 
An emerging concept in oncologic treatment is targeting of cancer stem cells 
(CSC), a subpopulation of self-renewing tumor cells capable of reinitiating and 
recapitulating all cells within the tumor (93). Because radiotherapy and traditional 
chemotherapeutics tend to target rapidly proliferating cells, the relatively quiescent state 
of CSC may allow them to evade these treatments and thus cause recurrent or metastatic 
disease. CSC have been identified in multiple cancers, including myeloid leukemia (94), 
HNSCC (95), colorectal (96), pancreatic (97), and neurologic cancers (98). Typical 
markers used to identify stem-like cells include aldehyde dehydrogenase 1 (ALDH1) 
(99), aldehyde dehydrogenase activity (100), CD44 (95), CD34/CD38 (94), and CD133 
(96).  
 
Cancer Stem Cells in ACC 
 Preliminary evidence suggests that ACC may contain cancer stem cells. One 
study isolated cells with high expression of ALDH1 (ALDH1high) from cells with low 
expression of ALDH (ALDH1low) in primary ACC tumors and ACC xenografts (101). 
Injection of these separated cells into NOD/SCID mice revealed that ALDH1high cells are 
more tumorigenic (24 of 60 tumors formed) compared with ALDH1low cells (5 of 126 
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tumors formed). Tumors formed from ALDH1high cells maintained histological patterns 
reminiscent of clinical ACC specimens (101). Interestingly, ALDH1high cells formed 
spheroids characteristic of stem cells seen in other neurologic cancers such as 
neuroblastoma (98). Given that ACC highly expresses common stem cell markers and 
shares expression profiles with other neurologically based cancers (51), ACC may be 
similarly driven by stem cells with neurologic or neural crest properties.  
 
Notch in Cancer Stem Cells 
 Notch has been identified as a critical mediator of CSC maintenance in many 
other cancer types including breast cancer (102), pancreatic cancer (103), embryonal 
brain tumors (104), and gliomas (105). The strongest evidence of Notch involvement in 
stemness maintenance is seen in breast carcinoma and glioblastoma cell lines, where 
blockade of Notch signaling by gamma secretase inhibition decreases the formation of 
spheroids containing stem-like cells (105, 106). Notably, gamma secretase inhibition 
specifically increases radiation-induced death of glioma CSCs while having relatively 
little effect on glioma bulk cells (107). In pancreatic cancer, Notch activation is 
associated with gemcitabine-resistant cells (108). These encouraging studies suggest that 
targeting of CSCs via Notch inhibition may have a potential role in treatment of 
radiation-resistant and chemo-resistant cancers, including ACC.  
While still a preliminary hypothesis, the presence of a stem-like population in 
ACC may, in part, be responsible for its high rate of recurrence and metastasis. Selective 
targeting of critical molecular mediators in this subpopulation may be a promising new 
approach in ACC treatment.  
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STATEMENT OF PURPOSE 
Hypothesis 
 Salivary ACC contains a subpopulation of cells with neural CSC-like properties 
driven by NOTCH1, SOX10, and FABP7 signaling. Inhibitors of Notch signaling may be 
effective in preventing CSC growth and radiation resistance, and thus has potential 
therapeutic relevance in ACC. 
 
Aims of this Study 
1. Establish and validate ACC cell cultures. 
Recent studies have found that existing ACC cell lines were contaminated or 
misidentified and did not represent ACC (61). We aim to establish and verify new ACC 
cultures from ACC xenografts and patient tumors, and if possible establish immortalized 
cell lines so that functional experimentation can be performed to better understand ACC 
biology. 
 
2. Identify, isolate, and characterize CSC from ACC specimens. 
We aim to build on existing studies suggesting the presence of CSC in ACC and 
identify markers to distinguish and isolate the CSC population. After isolating this 
population of cells, we will characterize their behavior and expression profile to assess 






3. Elucidate role of NOTCH and other molecular drivers of CSC in ACC. 
We aim to perform functional assays to determine potential roles and interaction 
of NOTCH, SOX10, and FABP7 in maintenance of CSC, and the mechanisms by which 
these mediators operate. 
 
4. Assess therapeutic role of NOTCH inhibition in ACC.  
Based on insights gained from in vitro studies of Notch signaling, we aim to 
evaluate the efficacy of Notch signaling inhibitors in the prevention of ACC tumor 
growth in culture and animal models. Additionally we assess the effect of Notch 
signaling inhibition on the ability of ACC cells to resist radiation.  
 
METHODS 
PDX and Primary Tumor Specimens 
Validated PDX models of ACC were obtained from Christopher Moskaluk at the 
University of Virginia (65). An additional clinical ACC specimen (ACC33) was collected 
from the Smilow Cancer Center at Yale New Haven Hospital, obtained through written 




5-10 mg of fresh or cryopreserved (90% FBS and 10% DMSO) tumor tissue 
underwent separate rinses with PBS, 70% EtOH, 100X Anti-Anti (GIBCO), and PBS 
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containing 1:500 ceftazidime. Tumor tissue was subsequently minced and transferred to a 
15mL plastic tube for digestion at 37ºC for 1-2 hours with occasional agitation. Digestion 
mixtures were comprised of 3 mL of complete DMEM media (DMEM with 10% fetal 
bovine serum (FBS), 1X Penicillin-Streptomycin, 1X L-Glutamine) supplemented with 1 
mL of dispase (BD Biosciences, San Jose, CA), 30-150 µL hyaluronidase (Sigma, St. 
Louis, MO), and 30-150 µL collagenase (Roche, Indianapolis, IN). Digested tissue was 
collected at 1,500 RPM for 3 minutes, rinsed with PBS, re-centrifuged, transferred into 3 
mL of F+Y culturing media (see below), and filtered using a 100 µm cell strainer. Tumor 
cells were then transferred to T-12.5 or T-25 flasks, depending on tumor volume, for 
culturing. Tumor cells were cultured together with either irradiated 3T3-J2 mouse 
fibroblast feeder cells or conditioned media derived from these cells (see below). Tissue 
processing was performed by both Michael Chang and Alex Panaccione. 
 
Cell Culture 
To establish a reliable ACC culture protocol, we modified a recently published 
epithelial cell culturing technique using Rho-kinase (ROCK) inhibitor and irradiated 3T3-
J2 mouse fibroblasts serving as feeder cells (109). Feeder cells were cultured in complete 
DMEM media and grown to confluency in T-175 flasks. Upon reaching confluency, cells 
were trypsinzied, washed, collected, and resuspended in fresh complete DMEM media. 
Feeder cells were irradiated with 30 Gy, counted, and immediately stored at 4oC for use 
up to 36 hours post-radiation. To create feeder cell conditioned media, irradiated 3T3-J2 
cells were incubated in a T-150 flask supplemented with 30 mL of DMEM media for 4 
days. Media was filter-sterilized and then mixed in a 1:4 ratio with F+Y culturing media. 
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F+Y culturing media contained 373 mL DMEM mixed with 125 mL F12 media (Life 
Technologies) that contained 7.5% FBS (Life Technologies), 10 ng/µL EGF, 5 µg/mL 
insulin (Sigma, St. Louis, MO), 250 µg/mL amphotericin (Fisher Scientific, Pittsburgh, 
PA), 10 mg/mL gentamicin (Life Technologies), 8.6 ng/mL cholera toxin (Sigma), and 
10 µM Y-27632, a ROCK inhibitor (Enzo Life Sciences, Farmingdale, NY). Cultured 
cells were derived from both PDX and patient tumor tissue. Cell culture work was 
performed by both Michael Chang and Alex Panaccione. 
 
Microsatellite Analysis 
To authenticate cell cultures and cell lines, we used the Promega GenePrint 10 
STR analysis PCR kit with fluorescent tagging. PCR products were analyzed on Applied 
Biosystems 3730xL DNA Analyzer at the Yale Keck Facility and data was processed 
using GeneMapper 3.7 software (Applied Biosystems). The results were cross-referenced 
with publically available STR databases to ensure unique STR signature 
(http://www.cstl.nist.gov/strbase/, http://www.dsmz.de/services/services-human-and-
animal-cell-lines/online-str-analysis.html). Microsatellite analysis was performed by Bea 
Carbone with assistance from Michael Chang and Alex Panaccione.  
 
Real-time RT-PCR 
To assess RNA transcript levels, RNA was isolated from frozen cell pellets of 
cells using RNeasy kit (Qiagen, Valencia, CA). cDNA was generated using iScript 
Reverse Transcriptase kit (Bio-Rad, Hercules, CA). Quantitative real-time RT-PCR was 
performed using iQ SYBR Green Supermix and CFX96 real-time detection system (Bio-
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Rad). β-actin was used as a normalizing control in all experiments. Real-time RT-PCR 
was performed equally by Michael Chang and Alex Panaccione.  
 
Western blot analysis 
To assess protein expression, western blot experiments were performed with the 
following antibodies: SOX10 (Abcam, ab155279), NOTCH1 (Cell Signaling, #3608), 
FABP7 (Cell Signaling, #13347), cleaved NOTCH1 (Cell Signaling, #4147), p27Kip1 
(Cell Signaling, #2552), SKP2 (Cell Signaling, #4313), β-actin (Santa Cruz, sc-47778), 
and GAPDH (Santa Cruz, sc-25778). Pre-cast gels and Rapid Turbo-blot System protein 
transferring equipment were purchased from Bio-Rad. Gels were imaged and quantified 
using Molecular Imager Gel Doc XR+ System with Image Lab software (Bio-Rad). 
Western blot analysis was performed equally by Michael Chang and Alex Panaccione. 
 
Immunofluorescence Staining 
Cells were plated onto 8-well glass slides at a density of 25,000-30,000 cells per 
well, incubated for 24 h, washed twice with PBS, and fixed with 3-4% paraformaldehyde 
at room temperature (RT) for 30 minutes. Cell were permeabilized with 0.15% Triton X-
100 in PBS for 5 minutes, washed twice, and blocked with 3% bovine serum albumin 
(BSA) for 30 minutes. Incubation with primary antibodies diluted in 3% BSA was 
performed at 4oC overnight with subsequent washing once with PBS and once with 3% 
BSA. The following antibodies were used: SOX10 (Abcam, ab155279), FABP7 (Cell 
Signaling, D8N3N), NOTCH1 (Cell Signaling, D1E11), SKP2 (Cell Signaling #4313), 
JAG1 (Santa Cruz, C-20), NR2F1 (Santa Cruz, sc-74561) NR2F2 (Parsons Proteomics, 
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H7147), and AlexaFluor secondary antibodies (Life Tech). Slides were imaged by 
confocal microscopy. Immunofluorescence experiments were performed equally by 
Michael Chang, Alex Panaccione, and Bea Carbone.  
 
CSC Isolation  
For separation of CD133+ and CD133- cells from bulk cultured cells or digested 
PDX tissue, cells were collected by trypsinization, rinsed in PBS, and filtered through a 
100 uM cell strainer to obtain a single cell suspension. Cells were labelled with CD133-
PE antibodies (Miltenyi, San Diego, CA) followed by CD133 Tumor Tissue MicroBead 
Kit (Miltenyi). Tumor cells underwent magnetic-activated cell sorting (MACS) by 
running through magnetic bead columns provided by Miltenyi. CD133+ and CD133- cells 
were collected in separate tubes, and CD133 expression for each was verified using real 
time RT-PCR. Based on our experience, MACS is faster and more efficient in sorting 
large cell numbers compared to flow cytometry-based sorting methods, and was overall 
less harmful to live ACC cells than flow cytometry.  CSC isolation was performed 
equally by Michael Chang and Alex Panaccione. 
 
Tumorigenicity Assays 
All mouse experiments were performed in accordance with NIH national 
guidelines and were approved by Yale Institutional Animal Care and Use Committee.  
Athymic nu/nu mice were purchased from NCI-Frederick (Frederick, MD). Mice were 
injected in the flanks subcutaneously with a specified number of viable tumor cells and 
measured weekly for tumor growth. Injected cells were either CD133+, CD133-, or bulk 
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tumor cells. Mice were sacrificed at a tumor volume of 1 cm3 or if complications from 
tumor burden developed. Statistical analysis for significant differences tumor growth was 
performed using the two-tailed t-test. Tumorigenicity assays were performed equally by 
Michael Chang and Alex Panaccione.  
 
Immunohistochemical Staining  
Tumor tissue was sectioned, fixed, and analyzed by IHC staining using the 
following antibodies: cleaved NOTCH1 (Cell Signaling, Val1744), SOX10 (Cell 




To assess effects of RNA knockdowns or DAPT treatment, cells either underwent 
DAPT versus DMSO treatment or transfection with siRNA against SOX10, NOTCH1, 
and FABP7 versus a control siRNA using lipofectamine in DMEM media. After 48-72 
hours, cells were collected and incubated with CD133-PE antibody (Miltenyi) for 10 
minutes. Fluorescence-activated cell sorting (FACS) was performed to determine 
percentage of CD133+ cells using a FACS Caliber BD machine. Data analysis performed 
using Flowing Software version 2.5.0. Flow cytometry was performed equally by 






Cells were seeded in 6-well plates at approximately 50% confluency. Cells were 
treated with 1 or 10 µM gamma-secretase inhibitor DAPT (synonyms GSI-IX, LY-
374973) from MedChem Express (Monmouth Junction, NJ) versus DMSO control, or 
using siRNA against NOTCH1, SOX10, and FABP7. At 24-hour intervals, 3 separate 
representative digital images per well at 4X magnification were used to quantify spheroid 
number. Statistical analysis was performed using a two-tailed t-test. Spheroidogenesis 
assays were performed by Michael Chang. 
 
Spheroid Depletion Assay 
Cells were seeded in 6-well plates at near-full confluency to allow for spheroid 
formation. After growth for 48 hours, cells were treated with varying concentrations of 
DAPT versus DMSO control. At 72 hour intervals, 3 separate representative digital 
images per well at 4X magnification were used to quantify spheroid number. Statistical 
analysis was performed using a two-tailed t-test. Spheroid depletion assays were 
performed by Michael Chang. 
 
Cell Proliferation Assay  
Cells were cultured in 96-well black clear bottom plates and treated with DAPT 
versus DMSO control. After cells were grown for 24-96 hours, viable cells were assessed 
by DNA quantification using the Cell Titer Glo system (Promega). Statistical analysis 
was performed using a two-tailed student t-test. Proliferation assays were performed by 
Michael Chang.  
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Cell Cycle Analysis  
After treatment with DAPT versus DMSO control or siRNA against SOX10 and 
NOTCH1, cells were slowly fixed in 70% cold ethanol and stained with propidium iodide 
(PI). A Fluorescence-activated cell sorting (FACS) Caliber BD machine was used to 
analyze cells. Data analysis was performed using Flowing Software version 2.5.0. Cell 
cycle experiments were performed equally by Michael Chang and Alex Panaccione. 
 
Cell Death Assay 
After treatment with DAPT for >72 hours, cells were incubated for 10 minutes 
with CD133-FITC antibody (Miltenyi) as well as Annexin V antibody and 7-AAD DNA 
stain (Annexin V:PE apoptosis detection kit I, BD Biosciences).  A FACS Caliber BD 
platform was used and data analysis was performed using Flowing Software version 
2.5.0. Cell death assays were performed equally by Alex Panaccione and Michael Chang.  
 
Radiation Sensitivity Assay 
Cells were plated in T-25 flasks and irradiated with 3 or 6 Gy using Mark I 
Cesium-137 irradiator followed by 48 hours of incubation in the presence or absence of 
DAPT. Following treatment, cells were stained with CD133-PE antibody. FACS was 
performed to determine percentage of CD133+ cells. Radiosensitivity assays were 
performed in triplicate with statistical analysis by a two-tailed student t-test. Radiation 




In Vivo Testing of DAPT Treatment 
In vivo efficacy of DAPT (SelleckChem, Houston, TX) was evaluated in an 
Accx11 xenograft model generated via subcutaneous injection of 106 cultured Accx11 
cells. Tumor cell-injected mice were randomized into control (vehicle-injected, N=5) and 
experimental (DAPT in corn oil, N=5) groups 15 days after cell injection. DAPT was 
administered intraperitoneally at 50%mg/kg, following an injection schedule of 3 days of 
treatment/4 days rest for 35 days. To assess DAPT toxicity, animals were observed daily 
and weighed weekly using a digital scale; data including individual and mean gram 
weights, mean percent weight change versus Day 0 and mean percent weight change 
versus prior measurement were recorded for each group and plotted at study completion. 
To assess DAPT efficacy, tumor dimensions were measured twice weekly by a digital 
caliper, and data including individual and mean estimated tumor volumes recorded for 
each group. Tumor volume (TV) was calculated using the formula TV=width2 × length × 
0.52. Statistical differences in tumor volume were determined using a two-tailed t-test. In 
vivo testing was performed by Alex Panaccione. Tumor processing was performed by 
Alex Panaccione and Michael Chang. 
 
RESULTS 
Generation and validation of cell cultures from ACC tissue 
 After the discovery that existing ACC cell lines were either contaminated or 
misidentified (61), the generation of new validated ACC cell lines is much needed to 
advance studies of this cancer. The rare incidence of ACC, however, limits the amount of 
clinical material available for culturing. To overcome this scarcity, we primarily used 
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tissue derived from previously verified PDX tumors (65) to generate new ACC cell lines. 
Through optimization of a recently published epithelial cell culturing protocol (109), we 
successfully generated intermediate- and long-term cell cultures from five ACC 
xenografts and one primary ACC tumor, Acc33 (Table 1). Successful cultures were 
derived from tumors with a diverse range of grades and histology. All six cultures 
proliferated for at least eight passages, with Accx11 and Acc33 reliably proliferating 
beyond 30 passages. 
 Cultures were primarily comprised of adherent spindle-shaped epithelial cells 
(Figure 1A). Of note, our most robust culture, Accx11, contained loosely adherent 
spheroid aggregates reminiscent of stem cells (Figure 1A, Accx11). All cultures yielded 
an adequate amount cells (>106) for molecular studies and cryopreservation.  
 To confirm the authenticity of newly created cell cultures, microsatellite profiling 
of eight sites was confirmed to match parental tumors (Table 2). Microsatellite profiles 
between culture and PDX tumors were near identical, with an acceptably small amount of 
drift as expected in culture environments. Cross-referencing these microsatellite profiles 
with those on publically available databases confirmed that these cell cultures were 
unique. 
 
Cultured cells express markers specific to ACC 
 Previously identified ACC markers were used to validate the identity of cultured 
cells. Expression of TrkC/NTRK3, SOX10, NOTCH1, and FABP7 were found nearly 
universally in clinical ACC specimens and linked to an ACC-intrinsic gene signature that 
contained ~200 genes (51, 52, 110). Reassuringly, real time RT-PCR found that all ACC 
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cell cultures expressed high levels all four genes that was higher than levels in normal 
salivary gland (NSG) tissue with the exception of NOTCH1 expression in Accx2, 
Accx19, and Accx29 (Figure 1B). SOX10, NOTCH1, and FABP7 were similarly found 
to be highly expressed in PDX tumors (Supplemental Figure 1). Combining microsatellite 
and marker expression verification, these data demonstrate that a ROCK inhibitor- and 
cell feeder-based protocol is an effective solution to the ACC cell culture problem, and 
that these techniques can be used to advance translational ACC research. 
 
ACC contains CD133+ spheroids that co-express SOX10, FABP7, NOTCH1, 
NOTCH1 targets, and neural stem cell markers 
SOX10, a key neural stem cell marker, has been identified as signature of stem 
cells in cancers originating from neural crest. The SOX10 co-expression profile identified 
in ACC (51) suggested existence in ACC of cells with CSC properties.  To validate this 
hypothesis, we profiled ACC for expression of cell surface markers that could be used for 
CSC isolation. Real time RT-PCR revealed that CD133/PROM1 (CD133), a cell surface 
marker of neural CSC (111), is expressed in all ACC cultures (Figure 1B) and ACC 
xenografts (Supplemental Figure 1).  
To better characterize CD133-expressing ACC cells, a robustly proliferating and 
spheroid-forming culture, Accx11 was further investigated. FACS analysis of multiple 
passages showed that 2-15% of cultured cells expressed CD133 (CD133+) (Supplemental 
Figure 2). Magnetic-activated cell sorting (MACS) separation of cultured Accx11 cells 
separated CD133+ and CD133- subpopulations as indicated by more than a 50-fold 
enrichment of CD133 expression (Figure 2A). Notably, CD133+ cells expressed at least 
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25-fold higher levels of SOX10, NOTCH1, and FABP7 compared to CD133- cells 
suggesting that expression of these genes co-segregated with cell surface expression of 
CD133 (Figure 2B).   
After separation, cultured CD133+ cells generated both spheroid-forming and 
tightly adherent cells, while cultured CD133- cells remained adherent and were not able 
to produce CD133+ cells or spheroids (data not shown). These data suggest that CD133+, 
but not CD133- cells, can reform both cell populations; however contamination of 
CD133+ cells with CD133- cells remained a possibility. To further explore stem 
properties of CD133+ cells, we investigated the expression of SCRG1, PLP1, MIA, 
SHC4, and TTYH1 that are components of the SOX10 co-expressed neural gene 
signature in ACC (51). Remarkably and without exception, these genes were more highly 
expressed in CD133+ ACC cells compared to CD133- cells (Figure 2B). Given the 
association of these genes with stem cells of neurologic cancers (112-115), their selective 
expression in CD133+ ACC provide additional support that ACC cultures contain neural 
stem-like cells (NSC).  
 Activation of Notch is a common feature of NSC and CSC (116) and Notch 
activation can be determined by levels of the intracellular domain (N1ICD). Western blot 
analysis revealed high expression of NOTCH1 and N1ICD in CD133+ compared with 
CD133- or unsorted Accx11 cells and confirmed high expression levels of SOX10 and 
FABP7 in CD133+ cells (Figure 2C). N1ICD is a marker of NOTCH1 activation as 
supported by increased expression of NOTCH canonical downstream targets HEY1, 
HEY2, and MYC in CD133+ cells (Figure 2D).  
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To determine if other ACC cultures harbored similar cell populations, cultured 
cells derived from an independent xenograft were examined. FACS analyses of Accx19 
cells found that 1-8% of total cells were CD133+ (data not shown). MACS separation of 
Accx19 cells produced approximately a 3-fold enrichment of CD133 expression in 
CD133+ cells compared to CD133- cells. In CD133+ Accx19 cells, expression of 
NOTCH1, SOX10, and FABP7 was similarly enriched (Supplemental Figure 3A). 
Overall, these data supported the existence of a previously unknown population of cells 
in ACC that express both CD133 and SOX10 and contain activated NOTCH1.  
 
CD133− ACC cells express neuronal differentiation markers NR2F1, NR2F2, 
p27Kip1, and Notch ligand JAG1  
ACC cells expressing CD133 expressed markers typically found in 
undifferentiated neural lineage, including NOTCH1 and SOX10. Since cells lacking 
CD133 expression expressed much lower levels of markers of stemness, expression of 
neural differentiation markers was determined. NR2F1 and NR2F2, two orphan nuclear 
receptors important in mediating NSC differentiation (117), were expressed at markedly 
higher levels in CD133- ACC cells compared to CD133+ cells (Figure 2E), suggesting 
that ACC cells lacking CD133 expression represent a more differentiated cell population. 
Finding neural differentiation markers in CD133- cells suggests that these more 
differentiated cells may have arisen from CD133+ ACC cells that express markers of 
neural stemness.  
JAG1, a canonical Notch ligand, is an activator of Notch signaling, and in many 
cancers it is expressed not in stem cells but in supporting niches (118, 119). Interestingly, 
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JAG1 expression was markedly higher (~11-fold) in Accx11 CD133- cells (Figure 2E). 
Similarly, NR2F2 and JAG1 were also expressed predominantly in CD133- cells isolated 
from Accx19 cultures (Supplemental Figure 3B). 
p27Kip1 is a cyclin-dependent kinase inhibitor that results in proliferative arrest 
and is a critical effector of neural differentiation whose expression is inhibited by 
activated NOTCH1 in NSC (120, 121). Given that in Accx11 cells NOTCH1 is 
preferentially activated in CD133+ cells (Figure 2C) and that CD133- cells express 
markers of neural differentiation (Figure 2E), expression of p27Kip1 was measured in 
both ACC populations. Immunoblotting of unsorted and CD133- Accx11 cells after 
sorting revealed significantly higher p27Kip1 levels compared to the CD133+ population 
(Figure 2F).   
 
Immunofluorescence analysis confirms unique molecular profiles of CD133+ and 
CD133- cells and supports NOTCH1/JAG1 interaction 
RNA and protein expression analysis suggest that two previously unknown and 
distinct subpopulations within ACC can be reliably identified using a series of molecular 
markers. Based on selective expression of NOTCH1 and its targets in CD133+ cells and 
JAG1 in CD133- cells, a model of inter-population signaling via NOTCH1/JAG1 
interaction is proposed (Figure 2G). Immunofluorescence staining of cultured Accx11 
cells supported this hypothesis with NOTCH1, SOX10, FABP7, and cell surface CD133 
staining detected in a distinct cell population associated with less firmly attached cells, or 
spheroids, and NR2F1, NR2F2, and JAG1 detected in adherent cells. CD133 
immunofluorescent staining was detected on a minority of cells within loosely adherent 
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cells that stained uniformly with NOTCH1 antibody, while the differentiation marker 
NR2F1 was detected only in the cytoplasm of adherent and more fusiform cells (Figure 
2H and 2I). Differentiation markers NR2F1 (cytoplasmic) or NR2F2 (nuclear) were 
present in the attached cell population, but below the level of detection in less adherent 
spheroids (Figure 2I, 2J, and 2K). Remarkably, NOTCH1-expressing cells within 
spheroids were closely surrounded by adherent cells expressing membrane-localized 
JAG1 (Figure 2L). Z stack images revealed that JAG1 and NOTCH1 were co-localized 
on adjacent surfaces of cells within adherent and spheroid cells, respectively (Figure 2L, 
see arrows). Combined, these data support the existence of two cell subpopulations in 
ACC, one being more stem-like with expression of SOX10 and NOTCH1 and one being 
more differentiated. A co-dependence of these cell populations is possible given the 
expression of JAG1 on more differentiated CD133- ACC cells and its receptor, NOTCH1, 
on CD133+ stem-like cells.  
 
CD133+ and CD133- populations identified in grafted ACC tissue   
To determine if subpopulations of differentiated and stem-like cells exist more 
generally in ACC and to validate in vitro findings, CD133 expression was determined in 
a series of ACC patient-derived xenografts and markers of stemness and differentiation 
correlated. After dissociation and MACS sorting of five ACC PDX tumors, cell counting 
of viable cells found CD133 expression in 21 to 65% of cells (Figure 3A). Real-time PCR 
revealed that CD133+ cells generally expressed higher levels of SOX10, NOTCH1, and 
FABP7 (Figure 3B, 3C, 3D, 3E). CD133- cells universally expressed higher levels of 
JAG1 with more variable expression level of NR2F1 (Figure 3F and 3G). These results 
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mirrored our findings in cultured cells, confirming the existence of two cell populations 
in ACC defined by expression phenotypes, SOX10+/NOTCH1+/FABP7+/CD133+ and 
JAG1+/NR2F1+/ CD133-. 
 
Tumorigenicity of ACC subpopulations  
The ability of cultured ACC cells to initiate tumors was investigated via 
subcutaneous injections of 106 cells into shoulder flanks of nude mice. Among ACC 
cultures tested to date, only Accx11 cells were tumorigenic in nude mice, forming tumors 
with solid histology and an intervening stromal component histologically similar to the 
parental patient tumor and PDX (Figure 4A). Relative expression of CD133, SOX10, 
NOTCH1, and FABP7 was similar in the original PDX and in the tumor produced from 
injection of cultured cells and higher than NSG as measured by RT-PCR and confirmed 
in tumor tissue by immunoblotting (Figure 4B and 4C).   
In various cancer types, CD133 expression defines populations of CSC with 
enhanced tumor-initiating properties (122). To investigate CSC properties of CD133-
expressing ACC cells, bulk Accx11 tumor cells were separated based on CD133 
expression by MACS and 104 cells were injected subcutaneously into right (CD133+) and 
left (CD133-) flanks of three nude mice. After 22 weeks, tumors were observed in 3 of 3 
sites injected with CD133+ cells, but in none of 3 sites injected with CD133- cells. At 32 
weeks, a single tumor formed at a site injected with CD133- cells. Histologic evaluation 
of the parental ACCX11 tumor, tumors derived from CD133+ cell injections, and the 
single tumor from a CD133- cell injection revealed similar histologic appearance 
(Supplemental Figure 4A). Expression analyses of CD133, SOX10, NOTCH1, and 
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FABP7 by real-time PCR and immunoblotting revealed expression of all markers in 
tumors derived from both CD133+ and CD133- cells (Supplemental Figure 4B and 4C) 
suggesting that injected CD133- populations can convert to CD133+ populations, or that 
separation of CD133+ and CD133- cells was incomplete. 
As experience with CD133 cell separation increased, we found that a single round 
of separation using CD133 antibody conjugated to beads left detectable traces of CD133+ 
cells in the CD133- population, reflecting technical limitations of this procedure. Also, 
separation decreased viability of CD133+ cells more than CD133- cells, possibly due to 
the damage inflicted by mechanical elution of column-bound cells (data not shown). To 
more adequately compare tumorigenicity of CD133+ and CD133- cells, a second round of 
magnetic separation was performed on the unbound cells to isolate a more pure CD133- 
population. Following this double separation, 105 viable cells of each population were 
injected into the flanks of nude mice. Tumors began to form at the sites of CD133+ 
injections as early as 6.5 weeks after injection. By 13 weeks post-injection, 4 of 5 
CD133+ injection sites had distinct tumors while none of 5 CD133- injections showed 
signs of tumor formation. Mean tumor volumes at 13 weeks were 0.14 cm3 for tumors 
derived from CD133+ and 0.01 cm3 for tumors derived from CD133- cells (Figure 4D) 
(p<0.05). With a marked delay, 2 of 5 injection sites of CD133- cell injections formed 
small tumors with the earliest tumor developing at 19 weeks. At 27.5 weeks, 5 of 5 
CD133+ injection sites formed tumors, while no additional tumors grew in CD133- 
injection sites. Overall, these experiments demonstrated enhanced tumorigenicity of 
CD133+ cells compared to CD133- cells.  
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Interdependence between NOTCH1, SOX10, and their common effector FABP7 
Essential individual roles for SOX10 and NOTCH1 in NSC maintenance are well 
established, and loss of Notch signaling decreases SOX10 expression in neural 
progenitors (123, 124). FABP7 has recently been described as critical for proliferation 
and prevention of differentiation in neural progenitors (125) and as a marker of 
aggressive clinical behavior in ACC (52). Given that SOX10, NOTCH1, and FABP7 are 
each implicated in neural stemness, their interdependence in ACC cells was studied. 
Following individual knockdowns, expression of all three genes was measured by RT-
PCR and immunoblotting. Depletion of SOX10 markedly decreased NOTCH1 expression 
and, reciprocally, knockdown of NOTCH1 was associated with decreased SOX10 both at 
the RNA and protein levels (Figure 5A and 5B). As expected, since FABP7 is a common 
target of NOTCH1 and SOX10 (56, 126), depletion of either NOTCH1 or SOX10 
markedly suppressed FABP7 RNA and protein levels. Interestingly, knockdown of 
FABP7 also had suppressive effects on RNA levels of NOTCH1 and SOX10. At the 
protein level, FABP7 had no obvious effect on NOTCH1 expression while modestly 
decreasing SOX10 levels (Figure 5A and 5B). These data suggest the interdependence 
and potential functional cooperation of SOX10, NOTCH, and FABP7.   
 Although individual roles of NOTCH1 and SOX10 in CSC and NSC survival are 
well established, their roles in ACC, as well as co-operation via FABP7 and possibly 
other effectors has not yet been studied. To begin exploring the role of FABP7 in ACC 
signaling, gene expression profiling was performed in Accx11 cells following FABP7 
depletion. Analyses revealed that 1158 genes were downregulated, and KEGG pathway 
analysis (http://bioinfo.vanderbilt.edu/webgestalt/) implicated these genes in cell cycle 
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regulation, ribosome biogenesis, cell metabolism, and signaling pathways regulating 
these processes (Table 3). Among these genes, 11 belonged to the Notch signaling 
network and 26 genes overlapped with the ACC SOX10 gene signature that we 
previously characterized (51). This observation further supported the feedback signaling 
from FABP7 to NOTCH1 and SOX10. In addition, SKP2, a major NOTCH1 effector 
involved in the regulation of cell cycle and proliferation (127), was among 31 cell cycle 
progression and 11 NOTCH1-regulated genes downregulated by FABP7 knockdown. In 
summary, these data suggested that NOTCH1, SOX10, and FABP7 may be co-regulated 
in ACC, and that FABP7 may serve as a pro-survival NOTCH1 and SOX10 effector. 
 
SOX10, NOTCH1, and FABP7 are required for spheroidogenesis  
NSC and CSC have the propensity to form spheroids in culture (128). Using 
spheroid formation as a surrogate of stem cell survival and proliferation, functional 
consequences of SOX10, NOTCH1, and FABP7 knockdowns were determined. 
Individual depletion of these genes significantly suppressed spheroid formation in 
cultured Accx11 cells (Figure 5C and 5D). These data suggested that SOX10, NOTCH1, 
and FABP7 are vital for spheroid formation, which could be due to a role in CSC survival 
and growth. Flow cytometry analysis of Accx11 was performed to assess the effects of 
SOX10, NOTCH1, and FABP7 depletion on cell cycle progression and cell survival. A 
marked (~4-6-fold) increase in the sub-G1 populations, indicating cell death, was 
observed following NOTCH1, SOX10, or FABP7 depletion (Figure 5E). Taken together, 
these results suggested that NOTCH1, SOX10, and FABP7 are important for survival of 
ACC cells, cell cycle progression, and maintenance of the stem-like subpopulation.  
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NOTCH1 depletion and gamma-secretase inhibition decrease CD133+ cells  
To test whether NOTCH1 is required for CD133+ survival, the percentage of 
CD133+ cells was measured following NOTCH1 knockdown in bulk Accx11 cells. 
NOTCH1 depletion resulted in a ~2.5-fold decrease in the proportion of CD133+ cells 
(Figure 6A). Pharmacologic inhibitors of SOX10 and FABP7 are not available for 
clinical use at this time, however Notch signaling inhibitors are available in the form of 
gamma-secretase inhibitors that have advanced to clinical trials (129). Bulk Accx11 cells 
treated with gamma-secretase inhibitor, DAPT, suppressed spheroid formation in a 
concentration-dependent manner (Figure 6B and 6C). To determine if Notch signaling 
was also required for maintenance of pre-formed spheroids, Accx11 was grown to 
confluency to allow spheroid formation. Over a 9-day time course, a dose-dependent loss 
of pre-formed spheroids was observed in DAPT-treated Accx11 cells compared to 
controls (Figure 6D); however, the effect of gamma-secretase inhibition on maintenance 
of preformed spheroids was not as dramatic as its effect on spheroidogenesis and 
plateaued after six days.  
To determine if DAPT activity was selective for CD133+ cells, ACC cells were 
separated by MACS then treated with DAPT for 72 hours. DAPT treatment suppressed 
proliferation of CD133+ cells with significant differences noted at all doses (1, 5, and 
10µm), while proliferation of CD133- cells was not affected (Figure 6E). FACS analysis 
confirmed a selective DAPT effect, demonstrating a ~2.5-fold increase in sub-G1 
population in CD133+ cells without altering cell cycle progression in CD133- cells 
(Figure 5F), suggestive of selective cell death in the CD133+ population. Annexin and 7-
AAD co-staining confirmed that DAPT treatment selectively killed CD133+ cells. 
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(Supplemental Figure 5). Interestingly, the pattern of cell death differed from that seen in 
apoptosis, suggesting an alternative cell death pathway induced by DAPT. Taken 
together, these data suggest that Notch signaling is critical in the proliferation and 
survival of CSC in ACC.  
 
Notch signaling inhibitors prevent ACC tumor growth in mice  
To perform a preclinical assessment of DAPT as a single agent treatment in ACC, 
Accx11 cells were injected subcutaneously into nude mice followed by 35-day treatment 
of peritoneally administered DAPT versus a vehicle control. In this study, DAPT had a 
statistically significant tumor-suppressive effect starting at two weeks (Figure 6G) 
without obvious signs of toxicity or loss of mouse weight. Overall, these in vitro and in 
vivo data suggest that Notch inhibitors could be advanced to clinical studies as a single-
agent therapy for ACC.   
 
Notch inhibition increases radiation sensitivity of CD133+ cells 
Because CSC are implicated in radiation resistance in many tumor types (122), 
the effect of targeting CD133+ cells through Notch inhibition in combination with 
radiation was determined by treating cells with DAPT for 24 hours before irradiation. 
Radiation alone had minimal effect on the proportion of CD133+ cells with 6 Gy of 
radiation decreasing this fraction only moderately, from 2.7 to 2.3%, (~15%) (Figure 
6H). However, DAPT as a single agent showed a two-fold (~56%) decrease in the 
proportion of CD133+ cells. Remarkably, when a single 3 Gy or 6 Gy dose of radiation 
was added to DAPT treatment, the combined effect resulted in an almost 2-fold 
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enhancement of CD133+ cell depletion as compared with DAPT alone. DAPT induced 
statistically significant (p<0.05) depletion of CD133+ levels at each dose of radiation 
when compared to radiation alone. The enhanced loss of CD133+ ACC cells following 
radiation in the presence of DAPT suggest that Notch inhibitors may have a role in 
sensitization of ACC cells to radiation.   
 
NOTCH1 depletion down-regulates SKP2, an E3 ubiquitin ligase that controls 
p27Kip1 
Activated NOTCH1 reduces p27Kip1 levels by stimulating expression of the 
p27Kip1 E3 ubiquitin-ligase, SKP2 (130). Identification of SKP2 downstream from a 
NOTCH1 effector, FABP7, suggested that SKP2 and p27Kip1 may be engaged in the 
survival and proliferative NOTCH1 signaling in stem-like ACC cells. Indeed, we 
observed decreased expression of p27Kip1 in CD133+ Accx11 cells, where NOTCH1 was 
activated (Figure 2C and 2F). Assessment of SKP2 expression by RT-PCR and 
immunoblotting showed enrichment of SKP2 in CD133+ compared to CD133- cells 
(Figure 7A and 7B). Immunofluorescent staining of Accx11 cultures revealed that SKP2 
was detected primarily in NR2F1-negative spheroidal cells, and was localized within the 
cytoplasm (Figure 7C), where it has been associated with oncogenic activity (131). Since 
SKP2 is a NOTCH1 transcriptional target, inhibition of NOTCH1 activity is expected to 
suppress SKP2 expression and, in turn, increase p27Kip1 protein stability and levels. In 
agreement with these expectations, siRNA-mediated NOTCH1 knockdown dramatically 
decreased SKP2 mRNA levels in Accx11 cells, as did DAPT treatment in a dose-
dependent manner (Figure 7D and 7E). To determine if Notch effects on SKP2 and 
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p27Kip1 are CD133+-selective, bulk Accx11 cells, CD133+, and CD133- populations were 
treated with DAPT for 48 hours then cell lysates subjected to immunoblot analysis. As 
expected, CD133+ cells expressed higher levels of N1ICD than bulk or CD133- cells, and 
DAPT effectively inhibited NOTCH1 activation as marked by decreased N1ICD in these 
cells (Figure 7F). SKP2 was readily detected in only CD133+ cells, whereas p27Kip1 was 
detected in CD133- cells at much higher levels than in CD133+ cells. Treatment with 
DAPT did not markedly alter expression of p27Kip1 in bulk or CD133- cells, but 
dramatically enhanced its expression in CD133+ cells (Figure 7F). Together, these data 
suggest a possible mechanism by which NOTCH1 inhibition decreases oncogenic activity 
in ACC is through downregulation of SKP2 and upregulation p27Kip1 selectively in 
CD133+ cells.   
 
DISCUSSION 
The significance of these studies lies partially in their ability to provide a 
framework and tools to begin addressing many of the current difficulties in ACC 
research. Advancements at both the basic science and clinical level include creation of 
validated cell cultures lacking widespread contamination previously observed in ACC 
cell lines (61) and providing a platform for pre-clinical studies to avoid continued high 
failure rates of clinical trials for systemic therapies in ACC (32). We demonstrate a new 
and effective method for culturing ACC cells from PDX and patient tumors, enabling 
functional experimentation and in-depth study of ACC biological drivers.  
While CD133 expression was recently reported in ACC (132), there have been no 
published attempts to isolate and characterize CD133+ ACC cells. Techniques described 
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here were used to isolate an enriched CD133+ population and characterize gene 
expression within this ACC subpopulation. Expression of SOX10, NOTCH1, FABP7, 
and multiple key neural stem cell regulators along with their potent tumor-initiating 
activity suggest that CD133+ expression marks a neural stem-like population of cells 
within ACC. Furthermore, we demonstrate a role of SOX10, NOTCH1, and FABP7 for 
proliferation and radiation resistance of CD133+ cells, identifying new potential pathways 
to target in ACC treatment. It will be interesting to determine if other molecular defects 
in ACC, including MYB fusions, are also involved in ACC stem cell survival or 
maintenance. Treatment for this cancer is in much need of a novel approach, and 
selective targeting of CSC may address issues of recurrence and relentless growth even 
after radiotherapy. 
Gene knockdown studies highlighted the essential roles and potential functional 
cooperation between NOTCH1 and SOX10 in maintenance of CD133+ ACC cells. An 
important and previously unappreciated insight into this cooperation was provided by the 
co-expression and interdependence of FABP7 with NOTCH1 and SOX10, as well as the 
role of FABP7 in regulating expression of genes critical for cell survival. FABP7 has 
been recently described as a novel diagnostic and prognostic ACC marker (52) and is also 
implicated in glioblastoma, melanoma, and basal-like breast cancer (53, 133, 134); 
however, its downstream targets and molecular mechanisms of activation have not been 
extensively studied. Data presented herein associated FABP7 with the expression of 
SKP2 and multiple other genes involved in survival, proliferation, and metabolic 
pathways identifying a novel signaling pathway that stimulates CSC in ACC. 
Importantly, these findings may extend beyond ACC to other cancers of neural origin in 
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which SOX10/NOTCH1/FABP7 signaling may also have crucial driving roles and 
therefore therapeutic relevance. 
As multiple Notch inhibitors have recently entered clinical trials for ACC, the 
findings of our study support the rationale behind these investigations. We demonstrate 
that a gamma secretase inhibitor selectively triggers cells death in tumor-initiating cancer 
stem cells, suggesting that Notch inhibitors have potential therapeutic roles in 
monotherapy or as an adjunct to initial surgery to prevent recurrence. Additionally, we 
demonstrate that CSC in ACC are sensitized to radiation when treated with a gamma 
secretase inhibitor, suggesting that Notch inhibitors may also have a significant 
neoadjuvant or adjuvant treatment role with radiation.  
Notch targeting with gamma-secretase inhibitors in trials for other cancers have 
been largely plagued by severe gastrointestinal side-effects attributed to the broad off-
target effects of gamma secretase inhibition. This has prompted the development and 
clinical testing of more specific inhibitors of Notch signaling, which include monoclonal 
antibodies against specific Notch receptors such as tareztumab (anti-Notch2/3) and 
brontictuzumab (anti-Notch1) as well as antibodies against activating ligands of Notch 
such as demcizumab and OMP-305B83 (both anti-DLL4) (OncoMed). Brontictuzumab is 
one of the drugs currently under investigation in a phase I trial for ACC. Multiple other 
small molecule inhibitors of the Notch pathway are in preclinical development.!
In this study we have also identified other potential therapeutic targets that can be 
the subject of future studies. Detection of JAG1 expression on the surface of CD133- 
ACC cells provides an important insight into evolutionary conserved molecular 
mechanisms of communication between CD133- and CD133+ cells. Since JAG1 
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expression in cancer has been linked to angiogenesis, chemoresistance, and poor survival 
(118), JAG1 targeting may provide additional means for therapeutic interventions aimed 
at both CD133- and CD133+ cell populations. 
Association of NOTCH1 activation with SKP2 and p27Kip1 provided an 
interesting insight into CSC-specific signaling in ACC. In addition to its central roles in 
the regulation of proliferation, apoptosis, and senescence, which are mediated via p27Kip1 
(135), SKP2 is critically involved in tumor survival during energy stress (136, 137). 
SKP2 functions at a crossroad of many oncogenic signaling axes, suggesting that SKP2 
inhibitors may increase efficacy of future CSC-targeting ACC therapies when used in 
combination with Notch inhibitors.  
It is important to recognize the limitations of this study. Given the rarity and 
unpredictability of cancer, it is difficult to assess generalizability of our findings to all 
cases of ACC, as the majority of our in vitro investigations were performed in one or two 
cell lines, Accx11 and Accx19. However, our immunomagnetic sorting and expression 
analysis of all available patient-derived xenograft tumors suggest that CD133+ cells 
expressing a similar expression profile are found in the majority of ACC specimens, and 
that all tested ACC tumors from patients expressed a neural stem gene expression pattern 
based on SOX10 (51). Future studies should aim to perform these experiments in other 
cell cultures and lines to determine the external validity of our findings. Additionally, 
while microsatellite analyses show little drift from xenograft to tumor, all cultures 
derived from PDX tumors may have already selected for the most robustly proliferating 
cells. While we did have success in establishing one culture directly from tumor tissue, 
these efforts will need to be continued in the future to ensure that cultured cells represent 
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clinical specimens as reliably as possible. In our treatment of ACC cells, we recognize 
that gamma-secretase inhibitors are known to have several off-target effects in addition to 
interference with Notch signaling. Observation of similar outcomes with depletion of 
NOTCH1 was reassuring that the biologic response to gamma secretase activity was 
mediated largely through NOTCH inhibition, but animal studies could not be performed 
with more specific NOTCH inhibition. Therefore, some assays may have been 
unknowingly altered by off-target effects of gamma secretase inhibition, and future 
studies are needed with more specific Notch inhibitors to clarify the precise role of Notch 
in CD133+ cell maintenance and radiation resistance. 
Overall, characterization of neural stem-like cells in ACC and delineating 
signaling events essential for their maintenance provide a new concept for ACC treatment 
that focuses on the clinical significance of cancer cells with neural stem properties. 
Continued study into the characteristics of this newly identified subpopulation of cells 
has the potential to open additional therapeutic opportunities for a relentless cancer that 
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